42654 Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices 

www.cdc.gov/niosh/nora/councils/wrt/ 

agenda.html. 

FOR FURTHER INFORMATION CONTACT: 

Emily Novicki, M.A., M.P.H, 

(NORACoordinator@cdc.gov), National 

Institute for Occupational Safety and 

Health, Centers for Disease Control and 

Prevention, Mailstop E–20, 1600 Clifton 

Road NE, Atlanta, GA 30329, phone 

(404) 498–2581 (not a toll free number). 

SUPPLEMENTARY INFORMATION: On April 

24, 2018, NIOSH published a request for 

public review in the Federal Register 

[83 FR 17283] of the draft version of the 

National Occupational Research 

Agenda for Wholesale and Retail Trade. 

No comments were received. 

Dated: August 20, 2018. 

Frank J. Hearl, 

Chief of Staff, National Institute for 

Occupational Safety and Health, Centers for 

Disease Control and Prevention. 

[FR Doc. 2018–18168 Filed 8–22–18; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Breast Cancer 

in Young Women (ACBCYW); 

Cancellation of Meeting 

Notice is hereby given of a change in 

the meeting of the Advisory Committee 

on Breast Cancer in Young Women 

(ACBCYW); August 6, 2018, 1:00 p.m. to 

5:00 p.m., Eastern. 

The teleconference which was 

published in the Federal Register on 

June 18, 2018, Volume 83, Number 117, 

pages 28231–28232. 

This meeting is being canceled in its 

entirety. 

For Further Information Contact: 

Temeika L. Fairley, Ph.D., Designated 

Federal Officer, National Center for 

Chronic Disease Prevention and Health 

Promotion, CDC, 4770 Buford Hwy. NE, 

Mailstop K52, Atlanta, Georgia 30341, 

Telephone (770) 488–4518, Fax (770) 

488–4760. Email: acbcyw@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–18186 Filed 8–22–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–FY–2018; Docket No. CDC–2018– 

0063] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled ‘‘HIV prevention among Latina 

transgender women: Evaluation of a 

locally developed intervention’’. The 

collection is part of a research study 

designed to evaluate the efficacy of a 

locally developed and culturally 

congruent two-session Spanish-language 

small-group intervention, ChiCAS 

(Chicas Creando Acceso a la Salud 

[Chicas: Girls Creating Access to 

Health]), which provides combination 

HIV prevention services to adult 

Hispanic/Latina transgender women at 

high risk for HIV infection. 

DATES: CDC must receive written 

comments on or before October 22, 

2018. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2018– 

0063 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Leroy A. 

Richardson, Information Collection 

Review Office, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, MS–D74, Atlanta, Georgia 

30329; phone: 404–639–7570; Email: 

omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

HIV prevention among Latina 

transgender women: Evaluation of a 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices 42655 

locally developed intervention—New— 

National Center for HIV/AIDS, Viral 

Hepatitis, STED, and TB Prevention 

(NCHHSTP), Centers for Disease Control 

and Prevention (CDC) 

Background and Brief Description 

The National Center for HIV/AIDS, 

Viral Hepatitis, STD and TB Prevention 

is requesting approval for 20-months of 

data collection entitled, ‘‘HIV 

prevention among Latina transgender 

women: Evaluation of a locally 

developed intervention.’’ The goal of 

this study is to evaluate the efficacy of 

ChiCAS (Chicas Creando Acceso a la 

Salud [Chicas: Girls Creating Access to 

Health]), a locally developed and 

culturally congruent two-session 

Spanish-language small-group 

combination intervention designed to 

promote consistent condom use, and 

access to and participation in preexposure prophylaxis (PrEP) and 

medically supervised hormone therapy 

by HIV seronegative Hispanic/Latina 

transgender women who have sex with 

men. 

The information collected through 

this study will be used to evaluate 

whether the ChiCAS intervention is an 

effective HIV-prevention strategy by 

assessing whether exposure to the 

intervention results in improvements in 

participants’ health and HIV prevention 

behaviors. The study will compare pre- 

(baseline) and post-intervention (sixmonth) levels of HIV risk among 

participants who have received the 

intervention and participants who have 

not yet received the intervention 

(delayed-intervention group). 

This study will be carried out in five 

metropolitan areas in North Carolina: 

Ashville, NC; Charlotte, NC; Research 

Triangle (metropolitan area of 

Greensboro, Winston-Salem and High 

Point NC); Raleigh, NC; and 

Wilmington, NC. The study population 

will include 140 HIV-negative Spanishspeaking transgender women. 

Participants will be adults, at least 18 

years of age, self-identify as male-tofemale transgender or report having 

been born male and identifying as 

female, and report having sex with at 

least one man in the past six months. 

We anticipate participants will be 

comprised mainly of racial/ethnic 

minority participants under 35 years of 

age, consistent with the epidemiology of 

HIV infection among transgender 

women. 

Intervention participants will be 

recruited to the study through a 

combination of approaches, including 

traditional print advertisement, referral, 

in-person outreach, and through word of 

mouth. A quantitative assessment will 

be used to collect information for this 

study, which will be delivered at the 

time of study enrollment and again at 

six-month follow up. The assessment 

will be used to measure differences in 

sexual risk knowledge, perceptions and 

behaviors including condom use, PrEP 

use and use of medically supervised 

hormone therapy. 

Intervention mediators, including 

healthcare provider trust and 

communication skills, self-reported 

health status and healthcare access, 

community attachment and social 

support will also be measured. All 

participants will complete the 

assessment at baseline and again at sixmonth follow-up after enrolling in the 

study. The intervention group will 

participate in ChiCAS after completing 

the baseline assessment and the delayed 

intervention group will participate in 

ChiCAS after completing the six-month 

follow up assessment. 

We will also examine intervention 

experiences through in-depth interviews 

with 30 intervention group participants. 

The interviews will capture 

participants’ general experiences with 

the ChiCAS intervention, as well as 

their experiences and perceptions 

specific to the main study outcomes: 

PrEP knowledge, awareness, interest 

and use; condom skills and use; and 

hormone therapy knowledge, 

awareness, interest and use. 

It is expected that 50% of transgender 

women screened will meet study 

eligibility. We expect the initial 

screening to take approximately four 

minutes to complete. The assessment 

will take 60 minutes (one hour) to 

complete and will be administered to 

140 participants a total of two times. 

The interview will take 90 minutes (one 

and one-half hours) to complete and 

will be administered to 30 participants 

from the intervention group one time. 

There are no costs to the respondents 

other than their time. The total 

estimated annualized burden hours is 

172. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

General Public—Adults ........ Eligibility Screener ................ 140 1 3/60 7 

General Public—Adults ........ Contact Information .............. 70 1 1/60 2 

General Public—Adults ........ Assessment .......................... 70 2 1.0 140 

General Public—Adults ........ Interview ............................... 15 1 1.5 23 

Total ............................... ............................................... .............................. .............................. .............................. 172 

Jeffrey M. Zirger, 

Acting Chief, Information Collection Review 

Office, Office of Scientific Integrity, Office 

of the Associate Director for Science, Office 

of the Director, Centers for Disease Control 

and Prevention. 

[FR Doc. 2018–18180 Filed 8–22–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Management Analysis and 

Services Office, CDC, pursuant to Public 

Law 92–463. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 


daltland on DSKBBV9HB2PROD with NOTICES